BioSpace News Archive

Company now focused on INTERLUDE CE Mark trial, building upon positive patient outcomes

Alteogen Inc. announced that it has successfully got an approval for orphan drug designation from the Food and Drug Administration with one of its assets for gastric cancer.

Marina Biotech, Inc. announced that the company has appointed Jay D. Schwartz to serve as Senior Vice President, Commercial Operations.

DURECT Corporation announced that its licensee, Pain Therapeutics reported that it received a Complete Response Letter from the U.S. FDA for Pain Therapeutics’ New Drug Application (NDA) for REMOXY® ER (oxycodone) extended-release capsules CII, which concluded that “The data submitted in [the] NDA do not support the conclusion that the benefits of [REMOXY] Extended-Release Capsules outweigh the risks.”

New publication details Foundation Medicine’s assay’s ability to measure bTMB and to identify patients who may benefit from anti-PD-L1 therapy

IDEXX Laboratories, Inc. (NASDAQ: IDXX), a global leader in veterinary diagnostics, veterinary practice software and water microbiology testing, will host its 2018 Investor Day on August 15-16, 2018 at its corporate headquarters in Westbrook, Maine.

TRIMEDX announced that Ramy Boghdadi has joined the company as its new Executive Vice President, Strategic Client Value and Relationships.

BioCryst Pharmaceuticals, Inc. announced the completion of an underwritten public offering of 10,454,546 shares of its common stock, including 1,363,636 shares sold pursuant to the exercise in full of the underwriters’ option to purchase additional shares.

ASLAN Pharmaceuticals reported financial results for the quarter ended 30 June 2018 and provided an update on its clinical activities.

The purchase price for this transaction consisted of cash, in addition to warrants.